RxDoctor Payments Data

Caroline Brown

Family · Sweetwater, TNNPI 1326822925

Payments from drug & device makers

$1,801in general payments, 2019–2025

Across 87 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$337
  • E.r. Squibb & Sons, L.L.C.$300
  • Atricure, Inc.$286
  • Boehringer Ingelheim$155
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$148
  • Kiniksa Pharmaceuticals International, PLC$129
  • plus $445 from 12 others

What the payments were for

  • Food & beverage$1,801100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,801 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$44,816
Medicare patients
314
Services billed
905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$100,314
JardianceEmpagliflozin29$36,453
EntrestoSacubitril/Valsartan29$28,989
XareltoRivaroxaban21$16,063
Repatha SureclickEvolocumab18$14,004
BrilintaTicagrelor28$13,626
Metoprolol Succinate93$1,297
Ezetimibe84$1,141
Valsartan35$1,049
Flecainide Acetate17$682
Atorvastatin Calcium55$504
Rosuvastatin Calcium44$475
Amiodarone Hcl21$426
Carvedilol47$410
ClopidogrelClopidogrel Bisulfate23$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$100,314110 claims
Boehringer IngelheimJardiance$155$36,45329 claims
AstraZenecaBrilinta$16$13,62628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Sweetwater

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →